Published in Iran Red Crescent Med J on October 02, 2016
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol (2013) 2.87
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2014) 2.47
Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med (2013) 2.46
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther (2014) 2.22
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology (2014) 2.17
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med (1997) 2.09
Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics (2009) 1.97
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84
Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med (2014) 1.50
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology (2012) 1.29
Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res (2007) 1.24
FDA approvals usher in the post-interferon era in HCV. Nat Biotechnol (2014) 1.18
Therapy of hepatitis C--back to the future. N Engl J Med (2014) 1.17
Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther (2013) 1.13
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2013) 1.11
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1997) 1.09
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther (2015) 1.07
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int (2014) 1.06
Direct medical care costs associated with patients diagnosed with chronic HCV. Hepat Mon (2013) 0.94
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther (2013) 0.92
Sofosbuvir has come out of the magic box. Hepat Mon (2013) 0.90
Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network. Hepat Mon (2014) 0.87
Estimation of private and social time preferences for health in northern Tanzania. Soc Sci Med (2005) 0.85
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res (2014) 0.85
Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol (2012) 0.84
Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients? Hepat Mon (2014) 0.79
Effect of Aerobic and Resistance Exercise Training on Liver Enzymes and Hepatic Fat in Iranian Men With Nonalcoholic Fatty Liver Disease. Hepat Mon (2015) 0.85
Economic burden of hepatitis B virus-related diseases: evidence from iran. Hepat Mon (2015) 0.81
Occult hepatitis B virus infection among hemodialysis patients. Hepat Mon (2012) 0.79
Comments on behavior of healthcare workers after injuries from sharp instruments. Trauma Mon (2014) 0.78
Predictive Factors in the Incidence of Cirrhosis in Chronic Hepatitis B Virus Infections. Hepat Mon (2016) 0.77
The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. Hepat Mon (2016) 0.77
Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-Analysis. Hepat Mon (2016) 0.77
Anti-Hepatitis E Antibody in Hemodialysis Patients in Isfahan, Iran: Prevalence and Risk Factors. Hepat Mon (2015) 0.76
Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. Hepat Mon (2014) 0.76
Necessity for Hepatitis B Surface Antigen Screening in Pregnant Females in Iran. Iran Red Crescent Med J (2016) 0.75
The HBsAg Prevalence Among Blood Donors From Eastern Mediterranean and Middle Eastern Countries: A Systematic Review and Meta-Analysis. Hepat Mon (2016) 0.75
FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection. Hepat Mon (2015) 0.75
A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model. Hepat Mon (2016) 0.75
Hepatitis B and its Relationship With Oxidative Stress. Hepat Mon (2016) 0.75
The Evaluation and Comparison of Transcriptionally Targeted Noxa and Puma Killer Genes to Initiate Apoptosis Under Cancer-Specific Promoter CXCR1 in Hepatocarcinoma Gene Therapy. Hepat Mon (2016) 0.75